The history of Sildenafil presents a challenging picture for investors. While the initial release generated substantial profits, the end of its intellectual property protection opened the floodgates to generic alternatives, dramatically eroding sales. This creates a specific risk for drug manufacturers depending on similar blockbuster medications,

The story of Viagra, and its creator copyright, presents a challenging case study for investors. Originally a blockbuster drug, producing billions in sales , its exclusivity period created a flood of lower-priced alternatives , significantly impacting its market share . While specific firms may try to capitalize on similar conditions , the current